Navigation Links
VistaGen, WARF sign license agreement for human embryonic stem cell technology
Date:12/18/2008

MADISON, VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools.

VistaGen, a biotechnology company based in South San Francisco, is one of the world's leading companies focused on using the power of stem cell technology to transform the ways drugs are discovered and tested. WARF is the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, one of the top-ranked public research universities in the U.S.

The licensed patents result from the research of stem cell pioneer James Thompson of the University of Wisconsin Stem Cell and Regenerative Medicine Center and director of regenerative biology at the new Morgridge Institute for Research. The license will accelerate VistaGen's commercial programs focused on providing customized, next-generation, stem cell-based predictive toxicology and drug discovery screening assays to increase preclinical research and development (R&D) productivity for the pharmaceutical industry.

"This agreement with WARF is another critical step in our strategy to become a 'one-stop-shop' for the world's premier stem cell differentiation systems," says Ralph Snodgrass, VistaGen's CEO. "It enhances our fundamental expertise for capturing the value of human embryonic stem cell biology for predictive toxicology, drug discovery screening and drug development. When combined with our strong stem cell-based intellectual property estate, the key terms of the new license provide a strong foundation to support our commercial programs focused on high-end R&D services, strategic discovery collaborations and enabling licenses."

"We are very pleased to have signed a licensing agreement with VistaGen," says Andy DeTienne, WARF's licensing manager for stem cell technologies. "VistaGen's approach to the commercialization of human embryonic stem cell technologies as next-generation tools for drug discovery and development in the pharmaceutical industry strongly complements our ongoing efforts to support growth of the human ES cell industry." He notes this licensing agreement with VistaGen demonstrates that commercial interest in human embryonic stem cells remains strong.

In 2009, VistaGen expects to launch a new era of R&D productivity in the pharmaceutical industry, an era driven by clinically relevant, commercially scalable, human biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. The company plans to use predictive information from its stem cell-based "Clinical Trials in a Test Tube" to increase the efficiency of identifying effective drug candidates and reduce clinical trial failures, especially failures due to heart or liver toxicity. VistaGen expects its next-generation stem cell-based human systems biology platform to dramatically enhance the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions.


'/>"/>

Contact: Janet L. Kelly
jkelly@warf.org
608-890-1491
University of Wisconsin-Madison
Source:Eurekalert

Related biology news :

1. L-1 Identity Solutions Awarded New Massachusetts RMV Drivers License Contract Valued at an Estimated $32 Million
2. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
3. Syntermed licenses Emory ERTb software for enhanced cardiac imaging
4. Iowa Corn Promotion Board, NJIT to license breakthrough, safe bio-plastic alternative
5. FSU, Magnet Lab researchers license critical petroleum data
6. Pfizer inks global license to Genomatix Software and databases
7. Integrated Fuel Technologies gets worldwide license for Argonne-developed Diesel DeNOx Catalyst
8. New high fiber barley licensed to grow
9. Springer and the Physiological Society of Japan sign publishing agreement
10. Saving Sumatra: Indonesia reaches historic agreement
11. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... an biological outbreak is about to be eliminated, said Lyle Probst, President, CEO ... FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample ...
(Date:9/19/2017)... Sunnyvale, California (PRWEB) , ... September 19, 2017 ... ... cell biology technologies, today announced a partnership with Cytena GmbH to launch the ... technology and real-time image analysis to isolate single cells and provide visual documentation ...
(Date:9/18/2017)... ... 18, 2017 , ... Transportable biomass conversion facilities and the ... is the topic of a September 27 webinar hosted by the ... transportable biomass conversion facilities for producing biochar, briquettes, and torrefied wood, biomass supply ...
(Date:9/18/2017)... (PRWEB) , ... September 18, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... ServiceMax Maximize 2017 conference. , What: Digital Transformation in Medical Device – The ...
Breaking Biology Technology: